https://www.selleckchem.com/products/GDC-0449.html
The predictive value of immune monitoring with circulating CD8 T lymphocytes for treatment response to programmed cell death protein 1 (PD-1) inhibitors has not been explored in non-small-cell lung cancer (NSCLC), prompting us to investigate whether dynamic changes in PD-1 CD8 T lymphocytes have predictive value for durable clinical benefit (DC and survival after PD-1 blockade. Patients with recurrent and/or metastatic NSCLC treated with PD-1 inhibitors were enrolled (discovery cohort; n=94). Peripheral blood was obtained immediately
Like
Comment
Share
